Chief Financial Officer — Bradford Amman: Mr. Amman resigned as Chief Financial Officer and Secretary, with an orderly transition plan in place.

Entry into a Material Definitive Agreement. The information set forth under

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of the Investors, the offer and sale of the Units, comprising the Preferred Stock and the Warrants, were made in a private placement transaction exempt from registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated there…

Entry into a Material Definitive Agreement. On June 30, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 4 LLC, a Wyoming limited liability company (“ V-Co 4 ”) and Bigger Capital Fund, LP (“ Bigger ”). V-Co 4 is a holder of more than 9.99% of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) and may be deemed an affiliate of the Company…

Entry into a Material Definitive Agreement. On June 10, 2026, Vivos Therapeutics, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with South Palm Cardiovascular Associates, LLC, a Florida limited liability company (“SPCVA”), pursuant to which the parties agreed to collaborate in the formation and operation of a new management services organization to be known as AIM Florida, LLC (“AIM Florida”). AIM Florida is intended to provide administrative, ope…

Regulation FD Disclosure. On June 10, 2026, the Company issued a press release announcing the Collaboration Agreement and the contemplated collaboration with SPCVA. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Other Events. On June 11, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its intention to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering, pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders. Subject to and following the SEC declaring the registration statement effective, the Company intends to distribute the rights as a di…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing…

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of V-Co 4, the offer and sale of the V-Co 4 Note was made in a private placement transaction exempt for registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. Neither the V-Co 4 Note nor any s…

Entry into a Material Definitive Agreement. Streeterville Capital, LLC Exchange Agreement As previously reported, Vivos Therapeutics, Inc. (the “ Company ”) is a party to a senior secured loan transaction, dated June 9, 2025, with Streeterville Capital, LLC, a Utah limited liability company (“ Streeterville ”), pursuant to which Streeterville previously made a loan to the Company in the form of a Secured Promissory Note (the “ Streeterville Note ”) with an original principal face amount of $8…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in Item 1.01, to the extent applicable, is hereby incorporated by reference into this

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under Nasd…

Results of Operations and Financial Condition. On April 15, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities…

Entry into a Material Definitive Agreement. On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”). V-Co 3 is an affiliate of New Seneca Partners Inc., a Michigan corporation (“ Seneca ”), a leading independent private equity firm and an existing sponsor of significant private investment in the Company. Pursuant to the PIPE…

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of V-Co 3, the offer and sale of the PIPE Shares and the Warrants was made in a private placement transaction exempt for registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. The PIPE Shares…

Director — Gregg C. E. Johnson: Appointment of Gregg C. E. Johnson as an independent director and member of the Compensation Committee.

Entry Into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into the following private placement transactions with an institutional investor (the “ Holder ”) pursuant to which the Company issued to the Holder (i) a Common Stock Purchase Warrant, issued on January 9, 2023, to purchase up to 266,667 shares of the common stock of the Company, par value $0.0001 per shares (the “ Common Stock ” and the warrant, the…

The Inducement Warrants, the Inducement Warrant Shares, the Placement Agent Warrants, and the shares of Common Stock underlying the Placement Agent Warrants have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”) and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder.

Entry into a Material Definitive Agreement. On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”). V-Co is an affiliate of New Seneca Partners Inc., an existing private equity investor in, and advisor…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of V-Co, the offer and sale of the Note was made in a private placement transaction exempt for registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. Neither the Note nor any securities of the…

Entry into a Material Definitive Agreement On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340 (the “ Principal Amount ”, and the financing as described herein, the “ Note…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.

Results of Operations and Financial Condition. On November 19, 2025, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Secur…

Other Information On October 24, 2025, Vivos Therapeutics, Inc. (the “ Company ”) filed a prospectus supplement to increase the aggregate offering price of the shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., dated February 14, 2025. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Ellenoff Grossman & Schole LLP relating to the lega…